查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1736635

2026 年至 2032 年核医市场类型、应用、最终用户和地区分析

Nuclear Medicine Market By Type, Application End-Users, Region for 2026-2032
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

核子医学市场评估（2026-2032）

心血管疾病、癌症、呼吸道疾病、神经系统疾病、代谢性疾病等慢性疾病的盛行率不断上升，是核医市场发展的关键驱动因素。因此，慢性疾病盛行率的上升将推动市场规模的成长，到2024年将突破68亿美元，到2032年将达到129.9亿美元的估值。

与传统医药相比，核子医学在医疗保健领域的应用尚处于起步阶段。然而，医学影像处理技术、放射性药物的进步以及人们对核医学益处的日益深入理解，正在推动核医学的应用。因此，核子医学在医疗保健领域的日益普及将推动市场在2026年至2032年间以9.30%的复合年增长率成长。

核子医学市场定义/概述

核子医学是一个跨学科领域，利用放射性物质或放射性药物来诊断和治疗各种疾病，包括神经病学、循环系统、内分泌系统疾病、消化器官系统疾病和癌症。放射性药物含有放射性示踪剂，注射到病人体内后会发射伽玛射线。这些辐射可被单光子发射电脑断层扫描 (SPECT) 和正子断层扫描 (PET) 等先进成像技术捕获，从而产生超越传统成像方法的高精度影像，有助于疾病的早期发现、准确诊断和全面检测。

放射性药物的最新进展提高了我们研究微观生理过程的能力，例如癌细胞增殖、心臟病中的心肌灌注、重症肺炎中的通气以及甲状腺功能亢进症中的甲状腺和副甲状腺活动。核子医学在下一代疗法的研发中得到越来越广泛的应用，包括放射性药物与抗体、生物药品和胜肽的结合物。这使得标靶药物传递、剂量优化和创新治疗方案的开发成为可能。因此，核子医学不仅是一种强大的诊断工具，而且在推动各个医学学科的治疗策略方面也发挥关键作用。

癌症和心血管疾病的日益普及将如何推动核医市场的成长？

根据世界卫生组织 (WHO) 的数据，癌症是全球首要的死亡原因，2020 年约有 1,000 万人死于癌症。根据美国心臟协会的报告，心血管疾病是全球首要的死亡原因，2019 年每年导致超过 1,790 万人死亡。放射性药物和诊断影像设备的技术进步根据 Verified Market Research 的调查，放射性药物市场预计在 2023 年价值 60.5 亿美元，到 2032 年将达到 136.1 亿美元，复合年增长率为 11.76%。

核子医学研发投入不断增加。美国能源局2021 财政年度用于核子物理研究的预算为 7.13 亿美元。欧盟委员会在欧洲原子能共同体 2021-2025 年研究与培训计画下为核子研究和培训活动拨款 13.8 亿欧元。个人化医疗的认知度和接受度不断提高 根据 Verified Market Research 的报告，个人化医疗市场预计将在 2023 年增长到 1302.3 亿美元，2032 年增长到 2725.9 亿美元，2026 年至 2032 年的复合年增长率为 10.67%。根据个人化医疗联盟的调查，73% 的肿瘤科医师为癌症患者使用个人化医疗检测。

放射性同位素在分子影像上的应用正在不断扩大。根据美国美国核能管理委员会的报告，美国每年进行约5,000万次核医检查。老年人口的增加以及随之而来的慢性病的增加是主要驱动因素。联合国报告称，全球65岁及以上人口的增长速度超过所有其他年龄段，预计到2050年将翻一番，达到15亿。世界卫生组织预测，到2030年，世界上六分之一的人将年龄在60岁或以上，这将增加对诊断和治疗核医程序的需求。

核子医学程序和设备的高成本将如何阻碍核医市场的成长？

核子医学检测和设备的高昂成本阻碍了核子医学市场的成长。根据美国放射学会的数据，在美国，PET/ 电脑断层扫描的平均费用为1,250至1,650美元，对许多患者来说过于昂贵。此外，监管要求也十分严格。美国美国核能管理委员会报告称，审查和核准一种新的放射性药物平均需要24个月。在欧洲，欧洲药品管理局（EMA）在2018年至2022年期间仅核准了三种新的放射性药物，凸显了核准流程的严谨性。

核子医学和分子影像学会指出，Technetium-99m 等常用放射性同位素的半衰期仅为 6 小时，这增加了物流的复杂性并增加了成本。 《核子医学杂誌》发表的一项研究表明，半衰期较短的放射性药物可能由于物流方面的挑战而导致高达 20% 的製备剂量无法使用。此外，熟练的核子医学技术人员也存在短缺。美国劳工统计局预测，从 2019 年到 2029 年，对核医技术人员的需求将增加 5%，但同时也指出，该领域规模较小，2019 年仅约有 18,000 个职缺。美国放射技术员学院的一项调查发现，2019 年核医技术人员职缺率为 4.7%，显示合格人员短缺。

目录

第一章 引言

  • 市场定义
  • 市场区隔
  • 调查时间表
  • 先决条件
  • 限制

第 2 章 已验证的市场研究调查方法

  • 资料探勘
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 研究流程
  • 业界专家的重要见解
  • 资料来源

第三章执行摘要

  • 市场概览
  • 生态测绘
  • 绝对的商机
  • 市场吸引力
  • 全球核子医学市场（按地区）
  • 全球核子医学市场类型
  • 全球核子医学市场（按应用）
  • 全球核子医学市场（按最终用户划分）
  • 未来市场机会
  • 世界市场结构
  • 产品生命线

第四章 市场概述

  • 全球核子医学的发展
  • 驱动程式
  • 限制因素
  • 机会
  • 波特五力模型
  • 价值链分析
  • 定价分析
  • 宏观经济分析

第五章 核子医学市场（按类型）

  • 概述
  • 诊断核子医学
  • PET放射性药物
  • SPECT放射性药物
  • 治疗性核子医学

第六章 核子医学市场：按应用

  • 概述
  • 肿瘤学
  • 神经病学
  • 循环系统

第七章 核子医学市场（依最终使用者）

  • 概述
  • 医院和诊所
  • 诊断中心

第八章 核子医学市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东和非洲
    • 阿拉伯聯合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲地区

第九章 竞争态势

  • 概述
  • 各公司市场排名
  • 主要进展
  • 公司地理分布
  • 公司产业足迹
  • ACE矩阵

第十章 公司简介

  • GE Healthcare
  • Curium Pharma
  • Novartis
  • Cardinal Health
  • Lantheus Medical Imaging
  • Jubilant Life Sciences Ltd
  • Nordion Inc.
  • Bracco Imaging SPA
  • The Institute for Radioelements（IRE）
  • NTP Radioisotopes SOC Ltd.

第十章 已验证的市场情报

  • 关于已验证的市场情报
  • 动态资料视觉化
简介目录
Product Code: 38092

Nuclear Medicine Market Valuation - 2026-2032

The increasing prevalence of chronic diseases such as cardiovascular diseases, cancer, respiratory disorders, neurological disorders, and metabolic conditions is a significant driver for the nuclear medicine market. Thus, the rising prevalence of chronic disorders surged the growth of market size surpassing USD 6.8 Billion in 2024 to reach a valuation of USD 12.99 Billion by 2032.

The adoption of nuclear medicine in the healthcare sector was at a nascent stage compared to traditional drug products. However, advancements in medical imaging technologies, radiopharmaceuticals, and the growing understanding of nuclear medicine's benefits have led to its increasing adoption. Thus, the increasing adoption of nuclear medicine in the healthcare sector enables the market to grow at a CAGR of 9.30% from 2026 to 2032.

Nuclear Medicine Market: Definition/ Overview

Nuclear medicine is a multidisciplinary field that utilizes radioactive materials, or radiopharmaceuticals, for the diagnosis and treatment of various diseases in areas such as neurology, cardiology, the endocrine system, the gastrointestinal system, and cancers. Radiopharmaceuticals contain a radioactive tracer that, when injected into the patient's body, emits gamma rays. These rays are captured by advanced imaging techniques like Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), enabling highly detailed images that aid in early detection, accurate diagnosis, and comprehensive examination of diseases, surpassing the capabilities of conventional imaging methods.

Recent advancements in radiopharmaceuticals have enhanced the ability to study micro-level physiological processes, such as cancer cell proliferation, myocardial perfusion in cardiac conditions, ventilation in severe pneumonia cases, and thyroid and parathyroid activity in hyperthyroidism. Nuclear medicine is increasingly used in research and development for next-generation therapies, including radiopharmaceutical conjugates with antibodies, biological drugs, and peptides. This enables targeted drug delivery, dose optimization, and the creation of innovative therapeutic solutions. As a result, nuclear medicine is not only a powerful diagnostic tool but also a key player in advancing therapeutic strategies across multiple medical fields.

How Does the Rising Incidence of Cancer and Cardiovascular Diseases Surge the Growth of the Nuclear Medicine Market?

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The American Heart Association reported that cardiovascular disease is the leading global cause of death, accounting for more than 17.9 million deaths per year in 2019. Technological advancements in radiopharmaceuticals and imaging equipment. According to the Verified Market Research, the Radiopharmaceuticals Market was valued at 6.05 billion in 2023 and is projected to reach USD 13.61 Billion by 2032, growing CAGR of 11.76%.

Increasing investment in nuclear medicine research and development. The U.S. Department of Energy's Office of Science budget for Nuclear Physics research was $713 million in fiscal year 2021. The European Commission allocated €1.38 billion for nuclear research and training activities under the Euratom Research and Training Programme 2021-2025. Growing awareness and acceptance of personalized medicine. According to the report of Verified Market Research the Personalized Medicine Market was valued at 130.23 Billion in 2023 and is projected to grow at 272.59 Billion by 2032, growing CAGR 10.67% from 2026 to 2032. A survey by the Personalized Medicine Coalition found that 73% of oncologists use personalized medicine testing for cancer patients.

Expanding applications of radioisotopes in molecular imaging. The U.S. Nuclear Regulatory Commission reported that approximately 50 million nuclear medicine procedures are performed each year in the United States. Increasing geriatric population and associated chronic diseases. The United Nations reported that the global population aged 65 and over is growing faster than all other age groups, expected to double to 1.5 billion by 2050. The WHO projects that by 2030, 1 in 6 people in the world will be aged 60 years or over, increasing the demand for diagnostic and therapeutic nuclear medicine procedures.

How does the High Cost of Nuclear Medicine Procedures and Equipment Impede the Growth of the Nuclear Medicine Market?

The high cost of nuclear medicine procedures and equipment hinders the growth of the nuclear medicine market. According to the American College of Radiology, the average cost of a PET/CT scan in the U.S. ranges from $1,250 to $1,650, which is prohibitively expensive for many patients. Stringent regulatory requirements. The U.S. Nuclear Regulatory Commission reported that it takes an average of 24 months to review and approve a new radiopharmaceutical. In Europe, the European Medicines Agency (EMA) approved only 3 new radiopharmaceuticals between 2018 and 2022, highlighting the rigorous approval process.

Short half-life of radiopharmaceuticals. The Society of Nuclear Medicine and Molecular Imaging noted that commonly used radioisotopes like Technetium-99m have a half-life of only 6 hours, complicating logistics and increasing costs. A study in the Journal of Nuclear Medicine found that up to 20% of prepared doses of short-lived radiopharmaceuticals go unused due to logistical challenges. Shortage of skilled nuclear medicine technologists. The U.S. Bureau of Labor Statistics projected a 5% growth in demand for nuclear medicine technologists from 2019 to 2029 but noted that the field is small, with only about 18,000 jobs in 2019. A survey by the American Society of Radiologic Technologists found that 4.7% of nuclear medicine technologist positions were vacant in 2019, indicating a shortage of qualified professionals.

Category-Wise Acumens

How the Diagnostic Imaging Technologies Foster the Growth of Diagnostic Nuclear Medicine Segment?

The diagnostic nuclear medicine segment dominates in the nuclear medicine market driven by advancements in diagnostic imaging technologies, such as the ability to capture high-resolution 3D images, faster device processing speeds, and increased automation. These improvements enhance the accuracy and efficiency of diagnosing various diseases, making nuclear medicine an essential tool in modern healthcare. Additionally, government interventions and the approval of numerous nuclear medicines for different disease treatments have accelerated the commercialization of these products, further expanding the segment's reach.

The development of a robust supply chain for radiopharmaceuticals and the availability of advanced infrastructure for the production and distribution of these medicines are also contributing to the segment's dominance. As a result, nuclear medicine is becoming more accessible, allowing healthcare providers to utilize cutting-edge diagnostic tools for early detection and precise treatment planning. These factors, coupled with growing healthcare investments and the demand for better diagnostic solutions, are expected to drive the market forward. The diagnostic nuclear medicine segment will continue to play a critical role in the healthcare landscape, improving patient outcomes and shaping the future of medical imaging and treatment.

How the Increasing Prevalence of Cancer Surge the Growth of Oncology Segment?

The oncology segment is set to dominate nuclear medicine driven by the increasing global burden of cancer. Changes in lifestyle, including unhealthy diets, smoking, and sedentary work habits, have significantly contributed to the rising incidence of cancer. Rapid urbanization has led to a larger population engaging in regular smoking, which remains a leading risk factor for various types of cancer. Additionally, sedentary lifestyles, characterized by minimal physical activity and a higher intake of processed and junk food, further exacerbate the cancer risk.

With cancer continuing to cause a significant number of deaths worldwide, there is a growing demand for more effective diagnostic and therapeutic tools. Nuclear medicine plays a critical role in oncology by offering highly advanced imaging techniques for early detection and precise diagnosis, which are crucial for improving treatment outcomes. Moreover, there has been a surge in investments aimed at developing novel radiopharmaceuticals and therapies specifically designed for cancer treatment. These advancements enable targeted treatment, improving patient outcomes while minimizing side effects.

Country/Region-wise Acumens

How Does the High Prevalence of Cancer and Cardiovascular Diseases Surge the Growth of the Nuclear Medicine Market in North America?

The increasing prevalence of cancer and cardiovascular disorders escalates the growth of nuclear medicine. According to the American Cancer Society, an estimated 1.9 million new cancer cases were diagnosed in the United States in 2021. The Centers for Disease Control and Prevention (CDC) reported that heart disease remains the leading cause of death in the U.S., accounting for about 659,000 deaths annually as of 2020. Strong research and development infrastructure The National Institutes of Health (NIH) budget for cancer research reached USD 6.56 Billion in fiscal year 2021, a significant portion of which supports nuclear medicine research. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) reported that over 20 million nuclear medicine procedures are performed each year in the United States.

Favorable Reimbursement Policies and Healthcare Spending. the Centers for Medicare & Medicaid Services (CMS) reported that national health spending in the U.S. grew 9.7% to $4.1 trillion in 2020, or $12,530 per person. A study published in the Journal of Nuclear Medicine found that Medicare reimbursement for PET scans increased by 14% between 2017 and 2020, encouraging wider adoption.

How does the Rapid Growth in Healthcare Infrastructure and Spending Foster the Growth of the Nuclear Medicine Market in Asia Pacific?

The growing healthcare infrastructure and high investment surge the growth of the nuclear medicine market in the Asia Pacific. According to the World Health Organization, healthcare spending in the Asia Pacific region was projected to grow at an annual rate of 7.1% between 2020 and 2024, outpacing the global average of 5.4%. China's healthcare expenditure reached 7.12 trillion yuan (approximately USD 1.1 Trillion) in 2020, a 10.2% increase from the previous year, as reported by the National Health Commission of China.

Increasing prevalence of cancer and cardiovascular diseases. The International Agency for Research on Cancer (IARC) estimated that in 2020, there were approximately 8.9 million new cancer cases in Asia, accounting for nearly half of the global cancer burden. The Asian Pacific Society of Cardiology reported that cardiovascular diseases accounted for 35% of all deaths in the Asia Pacific region in 2019, highlighting the need for advanced diagnostic and therapeutic options. Growing adoption of nuclear medicine technologies. The Indian nuclear medicine market was expected to grow at a CAGR of 10.5% between 2021 and 2026, driven by increasing government initiatives and rising awareness, as per a study published in the Journal of Nuclear Medicine Technology.

Competitive Landscape

The competitive landscape of the Nuclear Medicine Market is characterized by technological innovation, regulatory compliance, and a focus on providing high-quality, cost-effective services. Players must continuously invest in research and development, build strong partnerships, and adapt to evolving market trends to maintain a competitive edge.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the nuclear medicine market include:

  • Lantheus Medical Imaging, Inc.
  • Cardinal Health
  • Norgine B.V.
  • Nordion, Inc.
  • Bayer AG
  • Curium
  • Advanced Accelerator Applications
  • Bracco Diagnostic, Inc.
  • Jubilant Pharmova Limited
  • GE Healthcare (General Electric Company)

Latest Developments:

  • In April 2024, Curium announced the acquisition of EczacIbasI-Monrol Nuclear Product Co. This acquisition is expected to broaden its geographical reach, PET and SPECT infrastructure, and enable the development of cutting-edge radionuclide and radiopharmaceutical pipelines for diagnostic and therapeutic applications.
  • In February 2024, Curium reported that the Swissmedic had accepted their marketing authorization application for PYLCLARI, a novel (18F)-PSMA PET tracer, for evaluation.
  • In February 2024, Lantheus Holdings, Inc. announced the collaboration with the Consortium for Clarity in Alzheimer's Disease Research via Imaging (CLARiTI), which was financed by the National Institute on Aging.

Nuclear Medicine Market, By Category

  • Type:
  • Diagnostic Nuclear Medicine
  • PET Radiopharmaceuticals
  • SPECT Radiopharmaceuticals
  • Therapeutic Nuclear Medicine
  • Application:
  • Neurology
  • Cardiology
  • Oncology
  • End-Users:
  • Hospitals & Clinics
  • Diagnostic Centers
  • Region:
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL NUCLEAR MEDICINE MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Nuclear Medicine Market Geographical Analysis (CAGR %)
  • 3.6 Global Nuclear Medicine Market, By Type (USD Million)
  • 3.7 Global Nuclear Medicine Market, By Application (USD Million)
  • 3.8 Global Nuclear Medicine Market, By End-Users(USD Million)
  • 3.9 Future Market Opportunities
  • 3.10 Global Market Split
  • 3.11 Product Life Line

4 GLOBAL NUCLEAR MEDICINE MARKET OUTLOOK

  • 4.1 Global Nuclear Medicine Evolution
  • 4.2 Drivers
    • 4.2.1 Driver1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL NUCLEAR MEDICINE MARKET BY TYPE

  • 5.1 Overview
  • 5.2 Diagnostic Nuclear Medicine
  • 5.3 PET Radiopharmaceuticals
  • 5.4 SPECT Radiopharmaceuticals
  • 5.5 Therapeutic Nuclear Medicine

6 GLOBAL NUCLEAR MEDICINE MARKET BY APPLICATION

  • 6.1 Overview
  • 6.2 Oncology
  • 6.3 Neurology
  • 6.4 Cardiology

7 GLOBAL NUCLEAR MEDICINE MARKET, BY END-USERS

  • 7.1 Overview
  • 7.2 Hospitals & Clinics
  • 7.3 Diagnostic Centers

8 GLOBAL NUCLEAR MEDICINE MARKET BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 UAE
    • 8.6.2 Saudi Arabia
    • 8.6.3 South Africa
    • 8.6.4 Rest of Middle-East and Africa

9 GLOBAL NUCLEAR MEDICINE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Developments
  • 9.4 Company Regional Footprint
  • 9.5 Company Industry Footprint
  • 9.6 ACE Matrix

10 COMPANY PROFILES

  • 10.1 GE Healthcare
    • 10.1.1 Company Overview
    • 10.1.2 Company Insights
    • 10.1.3 Product Benchmarking
    • 10.1.4 Key Developments
    • 10.1.5 Winning Imperatives
    • 10.1.6 Current Focus & Strategies
    • 10.1.7 Threat from Competition
    • 10.1.8 SWOT Analysis
  • 10.2 Curium Pharma
    • 10.2.1 Company Overview
    • 10.2.2 Company Insights
    • 10.2.3 Product Benchmarking
    • 10.2.4 Key Developments
    • 10.2.5 Winning Imperatives
    • 10.2.6 Current Focus & Strategies
    • 10.2.7 Threat from Competition
    • 10.2.8 SWOT Analysis
  • 10.3 Novartis
    • 10.3.1 Company Overview
    • 10.3.2 Company Insights
    • 10.3.3 Product Benchmarking
    • 10.3.4 Key Developments
    • 10.3.5 Winning Imperatives
    • 10.3.6 Current Focus & Strategies
    • 10.3.7 Threat from Competition
    • 10.3.8 SWOT Analysis
  • 10.4 Cardinal Health
    • 10.4.1 Company Overview
    • 10.4.2 Company Insights
    • 10.4.3 Product Benchmarking
    • 10.4.4 Key Developments
    • 10.4.5 Winning Imperatives
    • 10.4.6 Current Focus & Strategies
    • 10.4.7 Threat from Competition
    • 10.4.8 SWOT Analysis
  • 10.5 Lantheus Medical Imaging
    • 10.5.1 Company Overview
    • 10.5.2 Company Insights
    • 10.5.3 Product Benchmarking
    • 10.5.4 Key Developments
    • 10.5.5 Winning Imperatives
    • 10.5.6 Current Focus & Strategies
    • 10.5.7 Threat from Competition
    • 10.5.8 SWOT Analysis
  • 10.6 Jubilant Life Sciences Ltd
    • 10.6.1 Company Overview
    • 10.6.2 Company Insights
    • 10.6.3 Product Benchmarking
    • 10.6.4 Key Developments
    • 10.6.5 Winning Imperatives
    • 10.6.6 Current Focus & Strategies
    • 10.6.7 Threat from Competition
    • 10.6.8 SWOT Analysis
  • 10.7 Nordion Inc.
    • 10.7.1 Company Overview
    • 10.7.2 Company Insights
    • 10.7.3 Product Benchmarking
    • 10.7.4 Key Developments
    • 10.7.5 Winning Imperatives
    • 10.7.6 Current Focus & Strategies
    • 10.7.7 Threat from Competition
    • 10.7.8 SWOT Analysis
  • 10.8 Bracco Imaging S.P.A
    • 10.8.1 Company Overview
    • 10.8.2 Company Insights
    • 10.8.3 Product Benchmarking
    • 10.8.4 Key Developments
    • 10.8.5 Winning Imperatives
    • 10.8.6 Current Focus & Strategies
    • 10.8.7 Threat from Competition
    • 10.8.8 SWOT Analysis
  • 10.9 The Institute for Radioelements (IRE)
    • 10.9.1 Company Overview
    • 10.9.2 Company Insights
    • 10.9.3 Product Benchmarking
    • 10.9.4 Key Developments
    • 10.9.5 Winning Imperatives
    • 10.9.6 Current Focus & Strategies
    • 10.9.7 Threat from Competition
    • 10.9.8 SWOT Analysis
  • 10.10 NTP Radioisotopes SOC Ltd.
    • 10.10.1 Company Overview
    • 10.10.2 Company Insights
    • 10.10.3 Product Benchmarking
    • 10.10.4 Key Developments
    • 10.10.5 Winning Imperatives
    • 10.10.6 Current Focus & Strategies
    • 10.10.7 Threat from Competition
    • 10.10.8 SWOT Analysis

10 VERIFIED MARKET INTELLIGENCE

  • 10.1 About Verified Market Intelligence
  • 10.2 Dynamic Data Visualization